Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and biomarkers for diagnosing and monitoring psychotic disorders

a psychotic disorder and biomarker technology, applied in the field of psychotic disorder diagnosis or monitoring, can solve the problems of significant delays in determining effective treatment and the inability to perform rapid assessment of drug respons

Inactive Publication Date: 2011-07-19
PSYNOVA NEUROTECH LTD
View PDF10 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent describes a method for diagnosing and monitoring psychotic disorders by measuring biomarkers in a sample from a subject. The biomarkers include proteins and peptides that are associated with the disorder. The method can be used to monitor the onset, progression, stabilization, amelioration, and remission of the disorder. The patent also describes a method for identifying substances that can stimulate or activate the production of biomarkers, which can be used in the treatment of the disorder. Overall, the patent provides a technical solution for developing new tools for diagnosis, monitoring, and treatment of psychotic disorders."

Problems solved by technology

Currently, there are significant delays in determining effective treatment and it has not hitherto been possible to perform rapid assessment of drug response.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0096]This Example describes experimental records and protocol for discovery of protein biomarkers for schizophrenia in serum using label-free relative quantitation by LC-MS / MS

1. Clinical Samples

[0097]Informed consent was given in writing by all participants and clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. Serum samples were collected from drug-naïve patients diagnosed with first episode paranoid schizophrenia or brief psychotic disorder due to duration of illness.

[0098]A total of 25 serum samples were analyzed: 13 first-onset drug-naïve schizophrenia patients and 12 healthy controls. The samples were stored at −80° C. and underwent a freeze-thaw cycle only once prior to preparation.

2. Sample Preparation

[0099]Serum samples were prepared blindly in random order using the following protocol:[0100]a) Each serum sample was depleted of the 20 most abundant proteins using the Sigma ProteoPrep20 immunoaffinity spin column kit....

example 2

[0147]Using a procedure similar to Example 1, 55 samples (22 schizophrenia patients, 33 controls), the putative peptide biomarkers given in Table 3 were found (* indicates depleted by antibodies).

[0148]

TABLE 3Ig Mu*p value 0.0011Apolipoprotein A1*p value 0.0175Apolipoprotein A2*p value 0.0253Serotransferrin*p value 0.0320Alpha-2-H5-glyconprotein precursorp value 0.0323

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

A method of diagnosing or monitoring a psychotic disorder, or predisposition thereto, comprises measuring, in a sample taken from a subject, the level of a biomarker selected from clusterin precursor, inter α-trypsin inhibitor, IgM, apolipoprotein A2 and α2 H5 glycoprotein.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is the U.S. National Phase of International Application PCT / GB2008 / 000199, filed Jan. 21, 2008, and published in English on Jul. 31, 2008, as WO 2008 / 090319; which claims benefit of the filing date of Great Britain Application No. 0701626.4, filed Jan. 22, 2007.TECHNICAL FIELD[0002]The present invention relates to methods of diagnosing or of monitoring psychotic disorders, in particular schizophrenic disorders (and bipolar disorders), e.g. using biomarkers. The invention also relates to use of biomarkers in clinical screening, assessment of prognosis, evaluation of therapy, drug screening and drug development. The biomarkers and methods in which they are employed can be used to assist diagnosis, and to assess onset and development of psychotic disorders.BACKGROUND OF THE INVENTION[0003]The identification of biomarkers for schizophrenic disorders permits integration of diagnostic procedures and therapeutic regimes. Current...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): G01N33/53A61B5/00G01N33/00
CPCG01N33/6896G01N2800/30G01N2800/302A61P25/18
Inventor LEVIN, YISHAIBAHN, SABINE
Owner PSYNOVA NEUROTECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com